Dörner Lutz, Fritsch Michael J, Hugo Hans H, Mehdorn H Maximilian
Department of Neurosurgery, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel 24105, Germany.
Surg Neurol. 2009 Jun;71(6):713-9, discussion 719. doi: 10.1016/j.surneu.2008.01.036. Epub 2008 Apr 18.
Primary diffuse leptomeningeal gliomatosis is a rare tumor disease affecting the leptomeninx of the CNS. It is thought to originate from subarachnoidal glial cell nests. The symptoms are often rather unspecific. Surgery is not an option and despite the use of chemotherapy and radiotherapy patients rarely survive for more than 12 months.
We present a case of PDLG in a 2-year-old girl, the youngest patient reported on so far. She presented with increasing somnolence, intermittent strabism, and vomiting. Magnetic resonance imaging of the cranium showed enlarged ventricles and contrast enhancement of the basal leptomeninx. Cerebrospinal fluid diagnostic studies showed a mild pleocytosis and elevated protein levels but no tumor cells or evidence of infection. A ventriculoperitoneal shunt was placed and a biopsy of the leptomeninx was taken in the right Sylvian fissure. The histopathology findings suggested a nonspecific meningeal inflammation. Because the girl developed spinal symptoms with paresthesia and hyperalgesia, a spinal MRI was performed which showed a similar contrast enhancement of the spinal leptomeninx. A spinal biopsy was taken and subsequently a paucicellular astrocytic tumor was diagnosed corresponding to a WHO I diffuse leptomeningeal gliomatosis. Chemotherapy with vincristine, carboplatin, and etoposide was initiated (Protocol SIOP-LGG 2004) but was stopped by the parents when the child was in partial remission after 50 weeks because of a neurologic deterioration. The girl has so far survived for more than 29 months.
Primary diffuse leptomeningeal gliomatosis must be included in the differential diagnosis of diffuse leptomeningeal contrast enhancement in young children. There are promising treatment options that need to be carefully evaluated.
原发性弥漫性软脑膜胶质瘤病是一种罕见的肿瘤性疾病,累及中枢神经系统的软脑膜。它被认为起源于蛛网膜下腔的神经胶质细胞巢。症状通常相当不具特异性。手术不是一种选择,尽管使用了化疗和放疗,患者很少能存活超过12个月。
我们报告一例2岁女孩的原发性弥漫性软脑膜胶质瘤病,这是迄今为止报道的最年轻患者。她表现为嗜睡加重、间歇性斜视和呕吐。头颅磁共振成像显示脑室扩大和基底软脑膜强化。脑脊液诊断研究显示轻度淋巴细胞增多和蛋白水平升高,但未发现肿瘤细胞或感染证据。放置了脑室腹腔分流管,并在右侧外侧裂取了软脑膜活检。组织病理学结果提示非特异性脑膜炎症。由于女孩出现了伴有感觉异常和痛觉过敏的脊髓症状,进行了脊髓磁共振成像,显示脊髓软脑膜有类似的强化。进行了脊髓活检,随后诊断为少细胞星形细胞瘤,符合世界卫生组织I级弥漫性软脑膜胶质瘤病。开始使用长春新碱、卡铂和依托泊苷进行化疗(SIOP-LGG 2004方案),但在50周后患儿部分缓解时因神经功能恶化被家长停止治疗。该女孩迄今已存活超过29个月。
原发性弥漫性软脑膜胶质瘤病必须纳入幼儿弥漫性软脑膜强化的鉴别诊断中。有一些有前景的治疗方案需要仔细评估。